2,1,3-Benzoxadiazol-4-amine, N-[2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]ethyl]-N-methyl-7-nitro- manufacturers
- FLTX1
-
- $53.00 / 1mg
-
2025-11-10
- CAS:1481401-71-1
- Min. Order:
- Purity: 98.46%
- Supply Ability: 10g
|
| | 2,1,3-Benzoxadiazol-4-amine, N-[2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]ethyl]-N-methyl-7-nitro- Basic information |
| Product Name: | 2,1,3-Benzoxadiazol-4-amine, N-[2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]ethyl]-N-methyl-7-nitro- | | Synonyms: | FLTX1;N-(7-Nitrobenzo[c][1,2,5]oxadiazol-4-
yl)demethyltamoxife;N-(7-Nitrobenzo[c][1,2,5]oxadiazol-4-yl)demethyltamoxifen;2,1,3-Benzoxadiazol-4-amine, N-[2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]ethyl]-N-methyl-7-nitro-;cancer,Estrogen Receptor/ERR,FLTX1,FLTX 1,Inhibitor,fluorescent,Tamoxifen,antiestrogenic,inhibit,non-permeabilized,receptor,breast,FLTX-1,estrogen,permeabilized,uterus;CB38231393;(Z)-N-(2-(4-(1,2-Diphenylbut-1-en-1-yl)phenoxy)ethyl)-N-methyl-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine;FLTX1, 10 mM in DMSO | | CAS: | 1481401-71-1 | | MF: | C31H28N4O4 | | MW: | 520.58 | | EINECS: | | | Product Categories: | | | Mol File: | 1481401-71-1.mol | ![2,1,3-Benzoxadiazol-4-amine, N-[2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]ethyl]-N-methyl-7-nitro- Structure](CAS/20200611/GIF/1481401-71-1.gif) |
| | 2,1,3-Benzoxadiazol-4-amine, N-[2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]ethyl]-N-methyl-7-nitro- Chemical Properties |
| Boiling point | 679.5±65.0 °C(Predicted) | | density | 1.258±0.06 g/cm3(Predicted) | | solubility | DMSO : 25 mg/mL (48.02 mM; Need ultrasonic) | | pka | -3.81±0.50(Predicted) | | form | Solid | | color | Orange to red |
| | 2,1,3-Benzoxadiazol-4-amine, N-[2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]ethyl]-N-methyl-7-nitro- Usage And Synthesis |
| Uses | FLTX1 is a fluorescent Tamoxifen derivative that can specifically label intracellular Tamoxifen-binding sites (estrogen receptors) under permeabilized and non-permeabilized conditions. FLTX1 exhibits the potent antiestrogenic properties of Tamoxifen in breast cancer cells. FLTX1 is devoid of the estrogenic agonistic effect on the uterus[1][2]. | | in vivo | FLTX1 (0.01-1 mg/kg/d; s.c. for 3 d) is lacked of the estrogenic uterotrophic (and also cervical and vaginal), hyperplasic and hypertrophic effects, and failed to alter basal proliferating cell nuclear antigen immunoreactivity in mice and rats[1]. | | IC 50 | ERα: 87.5 nM (IC50) | | References | [1] Marrero-Alonso J, et, al. Unique SERM-like properties of the novel fluorescent tamoxifen derivative FLTX1. Eur J Pharm Biopharm. 2013 Nov;85(3 Pt B):898-910. DOI:10.1016/j.ejpb.2013.04.024 [2] Morales A, et, al. Colocalization of Estrogen Receptors with the Fluorescent Tamoxifen Derivative, FLTX1, Analyzed by Confocal Microscopy. Methods Mol Biol. 2016;1366:163-173. DOI:10.1007/978-1-4939-3127-9_13 |
| | 2,1,3-Benzoxadiazol-4-amine, N-[2-[4-[(1Z)-1,2-diphenyl-1-buten-1-yl]phenoxy]ethyl]-N-methyl-7-nitro- Preparation Products And Raw materials |
|